/. and *. %<<, 1-%<&

~. , %. <. Jfil&, >. , !. Ja, /. J& et al., +)1-%& I, p.1

C. , /. &. , +. Db%&-",-&c-"-1+&t, *. %&-'%&-$-b+-*-k-'h-',, /. #n et al., W)'1+%&h'%&#, <&#%<&'1$1+%<&B+"W'1%<&*)$O+%&+%/,&#%&'N%CC%*+1C&hme&B%&q&%+&[eX& /Hb$>iL&>"&$)K%//%&#%<&#1CCB-%/*%<&%<+&O-)*D%&#%&q&hAa9MU&/Hb$>i&%+&*%''%&#%<&-"OO)-+<& O-)*D%&#%&p&hq9oXiL&

$. , %. Hb, $. , /. %. , <. $. et al., <<%<& h0, %&h4 M &Ç&q9[aiL&>%&H-"OD1T,%& & & pXa& *1A#%<<)+1)/&#%<&*)

3. , >. Jb, !. J&, %. , O. Y& et al., &J%-01*%&hG, R& A& !%<,-%<&ODK<1T,%<&-B"'1<B%<&O"-&I

/. %&, /. %&+b-1<+1t, and %. %<<, 1<& #y1, +1L& @%++%& hO%+1+%i& 0"-1"+1)

G. Uqaaqq&, /. Hb, $. >&-%-/-&-rh1t, %. , +. et al., &Q)/%&qAUq&/Hb$>&)Ü&'N%CC%+&ODK<1)'), &T,1&%<+&-"O1#%9& C"*1'%$%/+& #1<O)/1W'%9& C1"W'%& %+& O%,& *)á+%,<%&O%,+&V+-%&,+1'1<B%&O)&H%<+1)/&#%<&O"+1%/+<9&Y&*)/#1+1)/&T,%&'"&Q)/%&H-1<%&qA

W. %+&, /. &. , 1. /. Hb&-bob+-"-w-'%&-"-0%, and W. %o+, <&#%&'1$1+%<&#%&@S&B+W1'1+B&uamv&0)1-%&$V$%&Mq&}&uoqvL&>%&#)<"H%&#%<&+, +1)/<L&I)<&@S&<,-&'%<&#%,R& ",+)$"+%<& <%& <1+,%/+& %/+-%& X9m& %+& m9p& }L& >%<& @S& <)/+&+1)/&#%<&*)+1)/<&W"<<%<&$"1<&-%<+%/+&O"-C"1+%$%/+&"**%O+"W'%<L&@)$O+%&

$. %<,-%&#%&-'n5@g&%+&#, &. Hb, $. >&%+&o%, 0. /. +&-"-''%-&p, <. et al., Hb$>&h;?Fi&uX[vuopvL&& & >"&'1$1+%&#%&'1, -%& #%& q& Y& maq& /Hb$>L& >%& +%$O<& #%& +D-)$W1/%& #1',B& "OO

>. #%<&1-/, <. Ri&, #. =. B+, <. , $. +&#nb+ et al., H, 1<)/& & %<+& O%

3. , $. , O. J+-"-h-)-i&%, /. &o-b<%-/-*-%&#%&aqq&, /. Hb et al., H9&H, &%+&p&8Fb$>& #N;I3) hJ),-*%&s&#)<"H%<&-B"'1<B<&H1%&#,&@;8&#%&7)-#%, p.1

+. ). , #. , 1. #. , &. #n, /. O% et al., *+1C&?-1/1@>E?x&31W-1, +&h$B+D)#%&#%&@'",<<iL& & & & pee& </V/ %CFG8)G8)DB)JCBNEDEC7), pp.1-1

+. , /. B+, #. ). , /. %&, %. P. V+-%&-b+%-/-# et al., 1/%<& uopv& 0)1-%& O',<1%,-<& $)1<& ueavL& I, +1)/& <,-& *%<& $%<,-%<& C)/*+1)

O. , &. <. , O. , <. *. +%-&, /. %&-<++1c<9&-) et al., W1'1<"+1)/& h#%<&, 1T,N1'& %/& <)1+9& '%<& -B<,'+"+<& #%<& %<<"1<& #%& <+"W1'1+B&<)/+&<"+1<C"1<"/+<&O),-&'%&@IL& & & pem& 1L6]DFJEL6)

>. , +. , <. *. <%&-), %. #n, +. O% et al., H, +1&DBO"+1T,%9&#%&O)1#<&%R+-V$%9&'%&$)/1+)-"H%&#%<&*)1<%-& <1& O)<<1W'%& Y& #1<+"/*%& #%& '"& O-1<%& #,& $B#1*"$%/+9& *N%<+& Y& #1-%& %/& -B<1#,%'L& 5/& %CC%+9&'%<&$%<+1)/&uoXvL&@%O%

-. , F. , %. >%&-h-), and O. , +)1-%& h.F;:i& "& B+, +1T,%<&uoevL&G1/<19&'%&-1<T,%&DB$)--"H1T,%&%<+& *)/<1#B-B&*)$$%&C"1W'%&%/&*"<&#%&*)+1)/&1/CB-1%,-%&Y&Uq&

#. 3%1w-"-r&-), &. , #. , and %. *. Y&, iL& F'& %<+& 1$O), p.1

%. %&, /. &. <n-"-h1+&, /. #n, 1. %&-$-)-'b-*,-'%&-*-d-"-hb%&-t, . %<+&-*-"-o-"-w-'%& et al., H, +1*)"H

>. B&-y&-o-',, <. #%&-[-qqq&, %. %&o-',, <. /. Á+<&, #. Jb et al., 1<B<& h?:9& ?@G9& ?@c9& C1W-1, <&#%&*%++%&%<+1$"+1)/L&>"&0"'1#"+1)/&#%&*%<&$B+D)#%<&#%&#)<"H%&"&#)/*&%,& ,/&1$O"*+&C1BH'1H%"W'%&<,-&'%&W,#H%+&#,&'"W)-"+)1-%L& & & pmp& +#+?#,A&-23#%)

S. Publique, F. Lalande, I. Yeni, C. Laconde, and I. , La biologie médicale libérale en France!: bilan et perspectives Rapport pour un projet de réforme de la biologie médicale. Paris, ministère de la Santé, de la Jeunesse, des Sports et de la Vie associative NF EN ISO 15189-Laboratoires d'analyses de biologie médicale - Exigences particulières concernant la qualité et la compétence, NF EN ISO 22870-Analyses de biologie délocalisées (ADBD) -Exigences concernant la qualité et la compétence, 2006.

I. Gouin-thibault, P. Mismetti, C. Flaujac, X. Delavenne, S. Laporte et al., Nouveaux anticoagulants par voie orale: quelle place pour les analyses de biologie médicale?, STV Sang Thromb. Vaiss, vol.23, issue.1, pp.8-17, 2011.

S. C. Laizure, R. B. Parker, V. L. Herring, and Z. Hu, Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis, Drug Metabolism and Disposition, vol.42, issue.2, pp.201-206, 2014.
DOI : 10.1124/dmd.113.054353

G. J. Hankey and J. W. Eikelboom, Dabigatran Etexilate: A New Oral Thrombin Inhibitor, Circulation, vol.123, issue.13, pp.1436-1450, 2011.
DOI : 10.1161/CIRCULATIONAHA.110.004424

D. Garcia, E. Libby, and M. A. Crowther, The new oral anticoagulants, Blood, vol.115, issue.1, pp.15-20, 2010.
DOI : 10.1182/blood-2009-09-241851

M. M. Samama, The mechanism of action of rivaroxaban ??? an oral, direct Factor Xa inhibitor ??? compared with other anticoagulants, Thrombosis Research, vol.127, issue.6, pp.497-504, 2011.
DOI : 10.1016/j.thromres.2010.09.008

D. M. Adcock, S. K. Director, J. D. , and F. E. Frcpath, Sample Integrity and Preanalytical Variables, Quality in Laboratory Hemostasis and Thrombosis essor Vice Chair for Clinical Affairs, pp.31-42, 2008.
DOI : 10.1002/9781444303575.ch4

S. Yavordios, Les nouveaux anticoagulants oraux directs : r??le du laboratoire d???h??mostase, Revue Francophone des Laboratoires, vol.2014, issue.463, pp.37-51, 2014.
DOI : 10.1016/S1773-035X(14)72523-7

E. S. Eerenberg, J. Van-es, M. K. Sijpkens, H. R. Büller, and P. W. Kamphuisen, New anticoagulants: Moving on from scientific results to clinical implementation, Annals of Medicine, vol.37, issue.1
DOI : 10.1161/01.CIR.0000038501.87442.02

M. Schmohl, D. Gansser, V. Moschetti, and J. Stangier, Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to

M. Skeppholm, P. Hjemdahl, J. P. Antovic, J. Muhrbeck, J. Eintrei et al., On the monitoring of dabigatran treatment in ???real life??? patients with atrial fibrillation, Thrombosis Research, vol.134, issue.4, pp.783-789, 2014.
DOI : 10.1016/j.thromres.2014.06.016

J. D. Mullier, Suivi biologique des patients sous nouveaux anticoagulants oraux!: qui, quand, comment!?, Feuill. Biol, vol.LV, issue.319, 2014.

J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate

K. Linder and A. Strandberg, Hillarp, and Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

E. J. Favaloro and G. Lippi, The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Medica, pp.329-341, 2012.
DOI : 10.11613/BM.2012.035

E. Testa, A. Tiraferri, A. Tosetto, and C. Tripodi, Manotti, and Italian Federation of Thrombosis Centers Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA), Thromb. Haemost, vol.106, issue.5, pp.868-876, 2011.

G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement, Thrombosis Research, vol.127, issue.5, pp.457-465, 2011.
DOI : 10.1016/j.thromres.2011.01.001

M. J. Rhee, S. Morris, and D. P. Kosow, Role of meizothrombin and meizothrombin-(Des F1) in the conversion of prothrombin to thrombin by the Echis carinatus venom coagulant, Biochemistry, vol.21, issue.14, pp.3437-3443, 1982.
DOI : 10.1021/bi00257a029

G. Nowak, The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors, Pathophysiology of Haemostasis and Thrombosis, vol.33, issue.4, pp.173-183, 2003.
DOI : 10.1159/000081505

U. Lange, G. Nowak, and E. Bucha, Ecarin Chromogenic Assay ??? A New Method for Quantitative Determination of Direct Thrombin Inhibitors Like Hirudin, Pathophysiology of Haemostasis and Thrombosis, vol.33, issue.4, pp.184-191, 2003.
DOI : 10.1159/000081506

M. A. Miyares and K. Davis, Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient, American Journal of Health-System Pharmacy, vol.69, issue.17
DOI : 10.2146/ajhp110725

A. Fawole, H. A. Daw, and M. A. Crowther, Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban, Cleveland Clinic Journal of Medicine, vol.80, issue.7, pp.443-451, 2013.
DOI : 10.3949/ccjm.80a.13025

. Scharnhorst, Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays Which Assay Is Helpful?, Am. J. Clin. Pathol, vol.138, issue.4, pp.551-558, 2012.

R. C. Gosselin, D. M. Dwyre, and W. E. Dager, Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay, Annals of Pharmacotherapy, vol.47, issue.12, pp.1635-1640, 2013.
DOI : 10.1016/j.thromres.2011.01.001

J. Stangier and M. Feuring, Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran, Blood Coagulation & Fibrinolysis, vol.23, issue.2, pp.138-143, 2012.
DOI : 10.1097/MBC.0b013e32834f1b0c

M. M. Samama, C. Guinet, L. L. Flem, E. Ninin, and J. Debue, Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study, J

J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain et al., Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thrombosis Research, vol.130, issue.6, pp.956-966, 2012.
DOI : 10.1016/j.thromres.2012.09.004

J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain et al., Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thrombosis Research, vol.130, issue.6, pp.956-966, 2012.
DOI : 10.1016/j.thromres.2012.09.004

T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller et al., Measuring oral direct inhibitors of thrombin and factor??Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol.123, issue.4
DOI : 10.1111/jth.12149

A. Tripodi, V. Chantarangkul, C. Guinet, and M. M. Samama, The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in??vitro study, Journal of Thrombosis and Haemostasis, vol.8, issue.1
DOI : 10.1111/j.1538-7836.2010.04106.x

M. M. Samama, J. Martinoli, L. Leflem, C. Guinet, G. Plu-bureau et al., Assessment of laboratory assays to measure rivaroxaban ??? an oral, direct factor Xa inhibitor, Thrombosis and Haemostasis, vol.103, issue.4, pp.815-825, 2010.
DOI : 10.1160/TH09-03-0176

Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, Clinical laboratory measurement of & & pma& direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

. Sztark, Rivaroxaban and Apixaban in Orthopedics: is there a difference in their plasma concentrations and anticoagulant effects!?, Blood Coagul. Fibrinolysis, 2015.

S. Kitchen, E. Gray, I. Mackie, T. Baglin, and M. , Makris, and the BCSH committee Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology

J. Rönquist-nii, F. Dogné, and . Mullier, Is Dilute Russell's Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?, Blood, vol.122, issue.21, pp.3634-3634, 2013.

J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq et al., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.543-549, 2013.
DOI : 10.1160/TH13-04-0274

M. M. Samama, G. Contant, T. E. Spiro, E. Perzborn, C. Guinet et al., Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thrombosis and Haemostasis, vol.107, issue.2, pp.379-387, 2011.
DOI : 10.1160/TH11-06-0391

M. M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse, An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thrombosis and Haemostasis, vol.104, issue.5, pp.1078-1079, 2010.
DOI : 10.1160/TH10-03-0204

J. Douxfils, C. Chatelain, B. Chatelain, J. Dogné, and F. Mullier, Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide, Thrombosis and Haemostasis, vol.110, issue.2, pp.283-294, 2013.
DOI : 10.1160/TH12-12-0898

J. Harenberg, S. Du, C. Weiss, R. Krämer, D. Hoppensteadt et al., Walenga, and for the & & pmX& working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis, Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH

C. Ricós, V. Alvarez, F. Cava, J. V. García-lario, A. Hernández et al., Current databases on biological variation: pros, cons and progress, " Scand, J. Clin. Lab. Invest, vol.59, issue.7, pp.491-500, 1999.

I. Lacombe, W. Laboratory, and . Group, ACL TOP® Family Analytical Precision Performance Requirements, 2013.

A. European-medicines, Guideline on bioanalytical method validation, 2011.

C. G. Fraser, Inherent biological variation and reference values, Clinical Chemistry and Laboratory Medicine, vol.42, issue.7
DOI : 10.1515/CCLM.2004.128

. Grafmeyer, Réflexion sur le choix des limites acceptables dans les programmes d'évaluation externe de la qualité, Ann. Biol. Clin. (Paris), vol.65, issue.6, pp.677-684, 2007.

A. Vassault, D. Grafmeyer, and G. , Analyses de biologie médicale!: spécifications et normes d'acceptabilité à l'usage de la validation de techniques

E. M. Schmitz, K. Boonen, D. J. Van-den-heuvel, J. L. Van-dongen, M. W. Schellings et al., Determination of dabigatran, rivaroxaban and apixaban by UPLC-MS/MS and coagulation assays for therapy monitoring of novel direct oral anticoagulants, J

M. L. Rocci, V. Devanarayan, D. B. Haughey, and P. Jardieu, Confirmatory reanalysis of incurred bioanalytical samples, The AAPS Journal, vol.9, issue.3, pp.336-343, 2007.
DOI : 10.1208/aapsj0903040

J. M. Bland and D. G. Altman, Measuring agreement in method comparison studies, Statistical Methods in Medical Research, vol.8, issue.2, pp.135-160, 1999.
DOI : 10.1191/096228099673819272

B. Grenier, M. Dubreuil, and D. Journois, Comparaison de deux m??thodes de mesure d'une m??me grandeur??: m??thode de Bland et Altman, Annales Fran??aises d'Anesth??sie et de R??animation, vol.19, issue.2, pp.128-135, 2000.
DOI : 10.1016/S0750-7658(00)00109-X

I. Marseille and F. De-pharmacie, Etude des interférences de l'hémoglobine, de la bilirubine et des lipides sur 53 paramètres de biochimie, 1970.

C. Par and A. S. Vassaultonline, Recommandations pour l'accréditation des Laboratoires de!: Phase pré-analytique -Phase analytique, Biologie Médicale, vol.1

G. Dimeski, Interference Testing, Clin. Biochem. Rev, vol.29

M. Taylor, H. C. Whinna, A. M. Winkler, and S. Moll, Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, J. Thromb

J. Li, J. Fang, F. Zhong, W. Li, Y. Tang et al., Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50 µL rat plasma and its application to pharmacokinetic study, J

E. G. Nouman, M. A. , and H. M. Lotfy, Development and validation of LC???MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma, Journal of Chromatography B, vol.989, pp.37-45, 2015.
DOI : 10.1016/j.jchromb.2015.02.042

. Zahr, Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry, J

J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, British Journal of Clinical Pharmacology, vol.324, issue.3, pp.292-303, 2007.
DOI : 10.1345/aph.1D565

T. Ebner, K. Wagner, and W. Wienen, Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity, Drug Metabolism and Disposition, vol.38, issue.9, pp.1567-1575, 2010.
DOI : 10.1124/dmd.110.033696

P. Samama, P. Mismetti, and . Sié, Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) -mars 2013, Ann. Fr. Anesth. Réanimation, vol.32, issue.10, pp.691-700, 2013.

J. Douxfils, J. Dogné, F. Mullier, B. Chatelain, Y. Rönquist-nii et al., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate, Thrombosis and Haemostasis, vol.110, issue.3, pp.543-549, 2013.
DOI : 10.1160/TH13-03-0202

R. C. Gosselin, D. M. Dwyre, and W. E. Dager, Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay, Annals of Pharmacotherapy, vol.47, issue.12, pp.1635-1640, 2013.
DOI : 10.1016/j.thromres.2011.01.001

G. Rohde, Determination of rivaroxaban ??? a novel, oral, direct Factor Xa inhibitor ??? in human plasma by high-performance liquid chromatography???tandem mass spectrometry, Journal of Chromatography B, vol.872, issue.1-2, pp.43-50, 2008.
DOI : 10.1016/j.jchromb.2008.07.015

J. Pursley, J. X. Shen, A. Schuster, O. T. Dang, J. Lehman et al., LC???MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column, Bioanalysis, vol.6, issue.15, pp.2071-2082, 2014.
DOI : 10.4155/bio.14.66

J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq et al., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.543-549, 2013.
DOI : 10.1160/TH13-04-0274

. Lindhoff-last, Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin, Thromb. Haemost, vol.108, issue.1, pp.191-198, 2012.

H. Seifert, D. A. Stricker, W. A. Tsakiris, and . Wuillemin, Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9

J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq et al., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.723-731, 2013.
DOI : 10.1160/TH13-04-0274

V. M. Rosenoer, M. Oratz, and M. A. Rothschild, Albumin: Structure, Function and Uses, 2014.

. Cofrac, SH GTA 06-Guide technique d'accréditation!: contrôle de qualité en biologie médicale, 2012.

M. Sailstad, C. Khan, J. A. Ray, and . Wagner, Fit-for-purpose method development and validation for successful biomarker measurement, Pharm. Res, vol.23, issue.2, pp.312-328, 2006.

X. Delavenne, J. Moracchini, S. Laporte, P. Mismetti, and T. Basset, UPLC MS/MS assay for routine quantification of dabigatran ??? A direct thrombin inhibitor ??? In human plasma, Journal of Pharmaceutical and Biomedical Analysis, vol.58, pp.152-156, 2012.
DOI : 10.1016/j.jpba.2011.09.018

G. , V. Siguret, I. Gouin-thibault, and P. Sie, Dabigatran étexilate et examens de biologie médicale, 2013.

G. , I. Gouin-thibault, V. Siguret, and P. Sie, Apixaban et examens de biologie médicale, 2013.

G. , I. Gouin-thibault, and P. Sie, Rivaroxaban et tests de biologie médicale, 2012.

R. Leblanc, Le pr??-analytique en h??mostase et les recommandations du Groupe d?????tudes sur l???h??mostase et la thrombose (GEHT), Option/Bio, vol.20, issue.417, p.pp
DOI : 10.1016/S0992-5945(09)70113-8

G. , G. Pernod, and P. Albaladejo, Prise en charge d'un patient traité par dabigatran ou rivaroxaban, au long cours présentant une hémorragie ou nécessitant une chirurgie urgente, 2013.

A. Greinacher, T. Thiele, and K. Selleng, Reversal of anticoagulants: an overview of current developments, Thrombosis and Haemostasis, vol.113, issue.5, 2015.
DOI : 10.1160/TH14-11-0982

Y. Mo and F. K. Yam, Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.63, issue.Suppl, pp.198-207, 2015.
DOI : 10.1002/phar.1532

. Available, portola.com/clinical-development/andexanet-alfa-prt4445-fxa- inhibitor-antidote, 2015.

J. and .. !. 5<0+, 5:301.5'.!>!+::;.! 6+<&58123'!! 95:30185!1&:'&/1'! 930?'1,+&:'! 1&:'&/1'! =&:'&/1'! =&:'&/1'!&7&!/58':85! K5<0+, p.3

!. &. 7&&-', and . ^1, 00'30.!8':4&123'.!73! B17,7<123'.!>!'00'30, !:76A58'&:'.! >!I706+817&!:7&81&3'!>! 5?+,3+817&!/'!,+!I706+817&! :7&81&3'!

R. &7&e, +3(! H05,;?'6'&8! S+3?+1, 7<1'!'8!A+8477&.! S+&23'!/'!I706+817&!/'.! 5231A'.! :,1&123'.>80+&.A708>8':4&123'!, pp.4-81

!. 3. +14 and 1. !. , :&*1!X!! :&*1!, SSR! :&*1!#! "UV! S(T! "RT! SWV! :&*1!"@&!)!-4%%/&*!-5!3+24.+14,.&!-7A/B4*1+*&C!AD0,1+3!<&33&6.,%C!8AE!-&!F4.-&+5'G! ! !"#$%&'$($)* +, p.45

!. 3. +14 and 1. !. , )*0)12345* =&/$1;/*%"#$%&'$($)*0)12345* ?&@;));*<, Annexe, vol.13, issue.1

!. P. Kcjp=o and . Kf-!-!-!-"-#r-!, 106-21'!4>?5.-3603'!'6!4'!@701.0,-9-;2'A!?B/2609!@'99';12&A!C?D!4'!E-14'08(F N-30, Annexe, vol.1690

+. , V. !. Bk#, !. B. B0#-!.-b-"-#-!, B. !. , and *. &. , 967!C7!5-,9*+-)!CD+)*J(,+O+C75!C+,9?7!, évaluation de l'interférence de la lactescence pour le dabigatran :L-9J&7!M!C-))?75!C9!, pp.66-78

%. 0&, !1234)&.!0&!52!62, 54-*!0&.!/7+.&855&).!0&!597)0)&!0&, p.12